Bisphosphonate therapy for skeletal malignancies and metastases: Impact on jaw bones and prosthodontic concerns

Journal of Prosthodontics

Volumn 20, Issue 7, 2011, Pages 601-603

  Tripathi, Arvind ^a   Pandey, Saumya ^a   Singh, Saumyendra V ^b   Kumar Sharma, Naresh ^a   Singh, Ronauk ^a  

^a Saraswati Dental College and Hospital   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Bisphosphonates; BRONJ; Osteoprotegerin; RANK ligand

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN;

ALVEOLAR BONE LOSS; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; HUMAN; JAW OSTEONECROSIS; METABOLISM; METASTASIS; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; REVIEW; TOOTH IMPLANTATION; TOOTH PROSTHESIS;

ALVEOLAR BONE LOSS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DENTAL IMPLANTS; DENTAL PROSTHESIS RETENTION; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; RANK LIGAND;

EID: 80054702105     PISSN: 1059941X     EISSN: 1532849X     Source Type: Journal    
DOI: 10.1111/j.1532-849X.2011.00738.x     Document Type: Review

References (41)

1. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
2. Tsuda E, Goto M, Mochizuki S, et al: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-142.
3. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
4. Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
5. Katagiri T, Takahashi N: Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002;8:147-159.
6. Dougall WC, Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006;25:541-549.
7. Murthy RK, Morrow PK, Theriault RL: Bone biology and the role of the RANK ligand pathway. Oncology(Williston Park) 2009;23:9-15.
8. Guise TA: Molecular mechanism of osteolytic bone metastases. Cancer 2000;88:2892-2898.
9. Eck SM, Hoopes PJ, Petrella BL, et al: Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 2009;116:79-90.
10. Fili S, Kalarki M, Schallar B: Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related factors. Cancer Let 2009;283:10-19.
11. Holen I, Coleman RE: Bisphosphonates as treatment of bone metastases. Curr Pharm Des 2010;16:1262-1271.
12. Fleisch H: Bisphosphonates: pharmacology and use in treatment of tumor-induced hypercalcaemia and metastatic bone disease. Drugs 1991;42:919-946.
13. Mundy GR: Bisphosphonates as anti-cancer drugs. Drugs 1999;8:2009-2015.
14. Barni S, Mandala M, Cazzaniga M, et al: Bisphosphonates and metastatic bone disease. Ann Oncol 2006;17:ii91-ii95.
15. Neville-Webbe H, Coleman RE: The use of Zoledronic acid in the management of metastatic bone disease and hypercalcaemia. Palliat Med 2003;17:539-553.
16. Estefanía FR, Ponte FR, Aguirre UJM: Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Pathol Oral Cir Buccal 2006;11:456-461.
17. Gevorgyan A, Enepekides DJ: Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare. Curr Opin Otolaryngol Head Neck Surg 2008;16:325-330.
18. Sambrook PN, Ebeling P: Osteonecrosis of the jaw. Curr Rheumatol Rep 2008;10:97-101.
19. Rizzoli R, Burlet N, Cahall D, et al: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-847.
20. Marx RE: Reconstruction of jaw defects caused by bisphosphonate induced osteonecrosis of jaws. J Oral Maxillofac Surg 2009;67:207-219.
21. Allen MR, Burr DB: The pathogenesis of bisphosphonate related osteonecrosis of the jaw: so many hypotheses so few data. J Oral Maxillofac Surg 2009;67:61-70.
22. Allen M, Burr D: Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66:987-994.
23. Pazianas M, Miller F, Blumental WA, et al: A review of literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-1558.
24. Singh MM: Centchroman, a selective estrogen receptor modulator, as contraceptive, and in the management of hormone-related clinical disorders. Med Res Rev 2001;21:302-347.
25. Gennari L, Merlotti D, Nuti R: Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on Lasofoxifene. Clin Interv Aging 2010;5:19-29.
26. Deutertre M, Smith CL: Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295:431-437.
27. Gennari L, Merlotti D, Valleggi F, et al: Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;2495:361-379.
28. Clarke BL, Khosla S: New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol 2009;21:374-379.
29. Maeda T, Ke HZ, Simmons H, et al: Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies. Clin Calcium 2004;14:85-93.
30. Cummings SR, Ensrud K, Delmas PD, et al: PEARL study investigators: lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362: 590-599.
31. Lewiecki EM: Denosumab update. Curr Opin Rheumatol 2009;21:369-373.
32. Iguchi H: Molecular mechanism and potential targets for bone metastasis. Gan To Kagaku Ryoho 2007;34:1-10.
33. Ellis GK, Bone HG, Chlebowski R, et al: Effect of Denosumab on bone mineral density in women receiving adjuvant aromatic inhibitors for non-metastatic breast cancer: subgroup analysis of a phase 3 study. Breast Cancer Res Treat 2009;118:81-87.
34. Santini D, Fratto ME, Vincenzi B, et al: Denosumab: an era of target therapies in bone metastatic diseases. Curr Cancer Drug Targets 2009;9:834-842.
35. O'Donnell S, Cranny A, Wells GA, et al: Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006;3:CD005326.
36. Blake GM, Fogelman I: Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficiency. Clin Interv Aging 2006;1:367-375.
37. Deal C: Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009;5:174-181.
38. Deal C: Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009;21:380-385.
39. Ettinger B, San Martin J, Gauss G, et al: Differential effects of Teriparatide on bone mineral density (BMD) after treatment with Raloxifene or Alendronate. J Bone Miner Res 2004;19:745-751.
40. Maurya R, Singh G, Yadav DK, et al: Osteogenic activity of constituents from Butea monosperma. Bioorg Med Chem Lett 2008;19:610-613.
41. Bagi CM: Targeting of the therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 2005;57:995-1010.